Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 7Unknown 3Terminated 2Not yet recruiting 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Genitourinary 2Dermatologic 2Breast 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Advanced Ovarian Cancer 1

Interventions

pembrolizumab 45Paclitaxel 45Carboplatin 39Magnetic Resonance Spectroscopy 28olaparib 27Specimen Handling 26Cisplatin 24Bevacizumab 20Nivolumab 18Taxes 17Biopsy 16Gemcitabine 13Cyclophosphamide 13durvalumab 12Immunoglobulin G 11Doxorubicin 11Disulfides 11Surveys and Questionnaires 10niraparib 9liposomal doxorubicin 9dostarlimab 9Radiotherapy 8Brachytherapy 8lenvatinib 7fludarabine 7atezolizumab 7Letrozole 7Docetaxel 7cediranib 6Platinum 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Saline Solution × Gynecologic × Clear all
NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04065009 2024-01-11

IPLA-OVCA

Karolinska Institutet

Phase 3 Active not recruiting
220 enrolled
Gynecologic

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡